Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations

2024-10-25     Pierre Fabre Laboratories HaiPress

Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002,an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations

PFL-002/VERT-002 isa monoclonal antibody with a novel and differentiated mechanism of action,acting as a degrader of c-MET,with the potential to be a best-in-class treatment for cancer driven by MET alterations

CASTRES,France,Oct. 24,2024 -- PierreFabre Laboratories announced today that the first patient has been dosed with PFL-002/VERT-002,a monoclonal antibody acting as a degrader of c-MET,in a phase I/II first-in-human dose-escalation,dose-optimization and dose-expansion trial,for patients with Non-Small Cell Lung Cancer (NSCLC) harbouring MET alterations.

The PFL-002/VERT-002 phase I/II trial is an open label,multi-centre study that aims to assess the safety,tolerability,pharmacokinetics,pharmacodynamics and preliminary clinical efficacy of PFL-002/VERT-002,as a monotherapy for patients with MET-dependent tumors,including those emerging with acquired resistance to other treatments.

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer,accounting for approximately 85% of newly diagnosed lung cancer cases,and MET,also known as hepatocyte growth factor receptor (HGFR),is an oncogene driver in subsets of patients suffering from NSCLC.1-4MET exon 14 skipping mutation and MET amplification are found as primary oncogenic drivers and MET amplification as a resistance mechanism to selected targeted therapies.

"PFL-002/VERT-002 targets a clinically validated oncogenic driver with a unique and differentiated mechanism of action,triggering the degradation of the c-MET oncogene. Thus,it provides the opportunity to test a novel therapeutic approach for patients with MET driven tumors. We are looking forward to collaborating with the investigators participating in the first-in-human trial to assess the safety and efficacy of this new agent."saidFrancesco Hofmann,Head of Research and Development for Medical Care at Pierre Fabre Laboratories.

Contact: laure.sgandurra@pierre-fabre.com

PDF - https://mma.prnewswire.com/media/2538658/Pierre_Fabre_PFL_002_Vert_002.pdf


Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.